Physician profile
Blake Helget
NPI 1902288707
$2,466.21
in general payments reported to CMS, 2019-2025
24 companies · $193 in 2025
The $193 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $469 · 2020: $207 · 2021: $51.35 · 2022: $556 · 2023: $540 · 2024: $449 · 2025: $193.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,104 · Education: $78.44.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,104.05 |
| Education | $78.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $673.18 | 2019-2025 | |
| Lilly USA, LLC | $282.29 | 2019-2024 | Taltz, Olumiant, Ebglyss |
| Janssen Biotech, INC. | $215.48 | 2021-2023 | Tremfya |
| Amgen INC. | $187.95 | 2020-2025 | Otezla, Otezla |
| Leo Pharma INC. | $169.92 | 2023-2025 | Adbry, Anzupgo |
| Regeneron Healthcare Solutions, INC. | $148.61 | 2019-2025 | Dupixent |
| Allergan, INC. | $97.33 | 2019 | |
| Pfizer INC. | $86.77 | 2022-2023 | |
| Incyte Corporation | $85.36 | 2022-2024 | Opzelura |
| Galderma Laboratories, L.P. | $73.94 | 2019-2024 | |
| Genzyme Corporation | $62.93 | 2022-2024 | |
| Ucb, INC. | $59.41 | 2019-2024 | Bimzelx, Cimzia |
| Sun Pharmaceutical Industries INC. | $57.92 | 2022-2023 | Winlevi, Absorica Ld, Ilumya |
| Novartis Pharmaceuticals Corporation | $54.32 | 2019-2022 | |
| Arcutis Biotherapeutics, INC. | $45.05 | 2023-2024 | Zoryve |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almirall LLC | $31.79 | 2021 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $27.79 | 2019-2020 | |
| Blueprint Medicines Corporation | $20.97 | 2023 | Ayvakit |
| Sanofi-Aventis U.S. LLC | $18.05 | 2020 | |
| Vyne Pharmaceuticals INC. | $17.04 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $16.60 | 2024 | Sotyktu |
| Dermira, INC. | $14.45 | 2020 | |
| Dermavant Sciences, INC. | $13.52 | 2023 | Vtama |
| Organon LLC | $5.54 | 2025 | Vtama |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Blake Helget listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.